Week Ending January 3, 2022

The Lung Cancer Advocate Who Is a Friend to All
“A woman who has worked with Upal Basu Roy in the lung cancer space for many years explains why he is a lung cancer hero to everyone he has worked with, due to his dedication and empathy.”

A Deep Dedication to Improving Outcomes for Patients With Lung Cancer
“Dr. Hossein Borghaei credits mentorship early in his career with inspiring his interest in lung cancer and how immunotherapy can play a role in its treatment.”

Although Black/Hispanic Populations Remain Underrepresented in Clinical Cancer Trials, Participation Has Increased
“Despite Black and Hispanic patients continuing to be underrepresented in clinical cancer trials, minority participation has increased for diseases such as breast cancer, colorectal cancer, lung cancer, and prostate cancer, according to a study published in Cancer.”

Top 5 Most-Read Articles From Evidence-Based Oncology™ for 2021
“The rise of immunotherapy and precision medicine in both non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) is reflected in this year’s list of most-read articles in Evidence-Based Oncology™, the multistakeholder publication of The American Journal of Managed Care®. Disease states that have historically been the top causes of cancer death have seen progress in recent years, but 2021 brought some controversy.”

Biomarkers Light the Way for Personalized Treatment in NSCLC
“Jyoti D. Patel, MD, discusses biomarker testing, interpreting molecular result reports, and the growing armamentarium for patients with oncogene-driven lung cancer.”

Niu Discusses Use of Targeted Therapies in Various Patients With NSCLC
“Jason Niu, MD, director, Lung Cancer Program and associate director, Head & Neck Cancer Program at Banner MD Anderson Cancer Center, discusses an interesting non-small cell lung cancer patient case.”

Patritumab Deruxtecan Granted FDA Breakthrough Therapy Designation for Metastatic or Locally Advanced EGFR+ NSCLC
“Patritumab deruxtecan has been granted a breakthrough therapy designation by the FDA to accelerate its development for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies.”

Recap: Targeted Therapies for EGFR Exon 20 Insertion-Positive NSCLC
“In a recent OncView™ discussion, Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a lung cancer medical oncologist at Massachusetts General Hospital, in Boston, Massachusetts, discussed the identification and targeting of EGFR exon 20 insertion mutations in non–small cell lung cancer (NSCLC).”

Breaking the Stigma: Anyone Can Get Lung Cancer
“Heidi Nafman-Onda of Denver was just 55 years old when she felt a familiar pain. The lifelong fitness enthusiast and health educator had a history of ovarian cysts and suspected she’d developed another. She saw her gynecologist, but tests came back negative. Her doctor then sent her for a CT scan of her chest, abdomen and pelvis.”

Phoenix oncologist sees a rise in younger, non-smoking patients with lung cancer
“PHOENIX (3TV/CBS5) – A Valley oncologist wants to spread the word that you don’t have to be a smoker to be diagnosed with lung cancer. In fact, he is seeing more and more young, non-smokers with the diagnosis. His youngest lung cancer patient was a non-smoking 28-year-old.”

Stage 4 lung cancer patient credits her life to treatment at Atrium Health Levine Cancer Institute
“In January 2021, Ann Rich was eight years into her cancer journey when her lung cancer came back. By April, she couldn’t walk five feet without gasping for air. She said she felt like a prisoner in her own home, unable to walk far enough to even check the mail.”